Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004.


Journal Article

BACKGROUND AND METHODS: The high burden of respiratory infections in military populations is well documented throughout history. The primary pathogen responsible for morbidity among US recruits in training was shown to be adenovirus. Highly efficacious oral vaccines were used for 25 years, but vaccine production ceased in 1996, and available stores were depleted by early 1999. Surveillance for acute febrile respiratory illness was performed at eight military recruit training sites throughout the United States from July 1999 through June 2004 to document rates after loss of the vaccines. Laboratory diagnoses complimented the surveillance efforts. RESULTS: Over the 5 years, nearly 12 million person-weeks were followed and an estimated 110,172 febrile respiratory illness cases and 73,748 adenovirus cases were identified. Rates of illness were highest at the Navy and Air Force training centers, with average annual rates of 1.20 and 1.35 cases per 100 recruit-weeks, respectively. Adenoviral-associated illness rates peaked in weeks 3-5 of training, depending upon service. CONCLUSIONS: The burden of adenoviral illness among US recruit populations has returned to high levels since loss of the vaccines. Restoration of an effective adenovirus vaccine effort within the military is anticipated by 2008, potentially reducing the adenovirus morbidity suffered in this vulnerable population. Efforts to determine the burden of adenovirus and potential benefits of vaccination in civilian populations are being renewed.

Full Text

Duke Authors

Cited Authors

  • Russell, KL; Hawksworth, AW; Ryan, MAK; Strickler, J; Irvine, M; Hansen, CJ; Gray, GC; Gaydos, JC

Published Date

  • April 5, 2006

Published In

Volume / Issue

  • 24 / 15

Start / End Page

  • 2835 - 2842

PubMed ID

  • 16480793

Pubmed Central ID

  • 16480793

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2005.12.062


  • eng

Conference Location

  • Netherlands